AZNAstraZenecaRunning, no new patients
Capivasertib+Fulvestrant asTreatment for Locally Advanced(Inoperable) or Metastatic HR+/HER2- Breast Cancer in Chinese Patients
Breast Cancer
0Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 3
- Patients
- 293 (final count)
- Started
- Sep 26, 2024
- Main results expected
- Oct 31, 2026
- Fully finished
- Jan 10, 2027
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Time to first subsequent treatment (TFST) of PIK3CA/AKT1/PTEN-altered population in Cohort 1
Measured over: From the first dose of study intervention to the earlier of start date of the first subsequent therapy after discontinuation of study intervention, or death in PIK3CA/AKT1/PTEN-altered population in Cohort 1, up to approximately 2 years
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT06635447 · record last updated 2026-08-17 · checked 2026-11-09 15:47 UTC